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Fluoroquinolone antibacterial agents cause photosen-
sitivity dermatitis as an adverse effect and can func-
tion immunologically as photohapten. In a murine
model of quinolone photoallergy, Langerhans cells
are photomodi®ed with a systemically given quino-
lone upon ultraviolet A irradiation of skin and thus
present photohaptenic moieties to sensitize and resti-
mulate T cells. The aim of this study is to determine
the site of peptides/proteins photobound to quino-
lones and to assess the T cell antigenicity of quino-
lone-photocoupled peptides using Langerhans cells as
photoadduct-presenting cells. On an amino acid
composition analysis, lysine was preferentially
degraded in bovine serum albumin that was ultravio-
let A-conjugated with a representative quinolone
o¯oxacin. An af®nity chromatographic study using a
quinolone photoadduct-speci®c monoclonal anti-
body as ligand demonstrated preferential photocou-
pling of o¯oxacin with a lysine-containing peptide.
CD4+ T cells were puri®ed from lymph nodes of
BALB/c mice sensitized subcutaneously with o¯oxa-
cin-photomodi®ed epidermal cells and from those
sensitized epicutaneously via barrier-disrupted skin
with a major histocompatibility complex class II (I-
Ad)-binding, o¯oxacin-photoconjugated peptide.
These immune T cells proliferated in vitro in
response to Langerhans cells loaded with class II-
binding, lysine-containing peptides when photomo-
di®ed with o¯oxacin. Furthermore, epicutaneous
application of the o¯oxacin-photoconjugated peptide
was able to prime mice for subsequent elicitation of
photoallergy evoked with systemic o¯oxacin and
ultraviolet A light. This study suggests that lysine
affords quinolone photocoupling of peptides and
quinolone-photomodi®ed peptides on class II mol-
ecules stimulate pathogenetic T cells in quinolone
photoallergy. Key words: ¯uoroquinolone/photohapten/
photosensitivity/ultraviolet A. J Invest Dermatol 117:1206±
1211, 2001
F
luoroquinolone (FQ) antibacterial agents are well known
to cause photosensitive dermatitis as a side-effect
(Ferguson, 1995; Tokura, 1998). Ultraviolet (UV) A
light is the main action spectrum to elicit photosensitive
skin reactions in patients medicated with FQ (Kawabe et
al, 1989; Tokura, 1998). Both phototoxic (Wagai and Tawara,
1991; Fujita and Matsuo, 1994; Horio et al, 1994; Tokura et al,
1996a; Kawada et al, 1999) and photoallergic (Kawabe et al, 1989;
Horio et al, 1994; Tokura, 1998; Tokura et al, 1998) mechanisms
underlie the pathogenesis of FQ-induced photosensitivity, and the
photosensitive capacity varies depending on the type of FQ (Wagai
and Tawara, 1991; Horio et al, 1994; Tokura et al, 1998). For
example, spar¯oxacin is highly phototoxic and less photoallergic,
whereas other FQ are mainly photoallergic on a clinical basis
(Tokura et al, 1996a, 1998).
We have investigated the mechanisms of FQ photoallergy in
mice. The photoallergenicity of FQ is mainly derived from their
photohaptenic moiety. FQ are covalently coupled to protein by
UVA exposure (Tokura et al, 1996b). Because of this ability,
epidermal cells are photoderivatized with FQ upon UVA irradi-
ation, thereby initiating immunologic consequences (Tokura et al,
1996b, 1998). Among epidermal cells, the Langerhans cells are
critical, which are photomodi®ed with a systemically given FQ
upon UVA irradiation of the skin and become photohapten-
bearing, T cell stimulatory cells (Tokura et al, 1998; Ohshima et al,
2000). Murine FQ photosensitivity involves the activation of major
histocompatibility (MHC) class II-restricted, quinolone-photoad-
duct-speci®c, CD4+ Th1 cells expressing T cell receptor Vb13
(Tokura et al, 1998). There exists broad cross-reactivity among FQ,
suggesting that FQ carry the same haptenic epitope recognized by
Vb13+ T cells. The presence of T cells that react with FQ-
photomodi®ed syngeneic cells is also proven in patients with FQ
photosensitivity (Tokura et al, 1999).
There are some relationships between the chemical structure of
FQ and photoallegenicity. The piperazinyl (or methylpiperazinyl)
group, the major side chain of FQ linked at C7, is altered by UVA
irradiation (Yoshida and Moroi, 1993; Tiefenbacher et al, 1994),
and thus protein may be covalently bound to the piperazinyl ring
during its photodegradation to form an allergic FQ±protein
complex (Tokura, 1998). It remains to be elucidated, however,
whether this photobinding to protein/peptide occurs at the
particular amino acid residue(s). It has been reported that haptenic
drugs bound covalently to peptides with af®nity to MHC class II
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molecules induce T cell responses in the presence of antigen-
presenting cells, and these hapten±peptide conjugates are the
immunodominant determinants (Martin and Weltzien, 1994;
Weltzien and Padovan, 1998). Therefore, another issue to be
clari®ed is whether FQ-photomodi®ed peptides are antigenic for T
cells with Langerhans cells serving as photoadduct-presenting cells.
This might also provide evidence that FQ exert their antigenicity
when bound to self-peptides located on MHC molecules (Chien
and Davis, 1993). Here, using o¯oxacin (OFLX) as a representative
FQ (Schiefe et al, 1993; Ronnau et al, 1997), we demonstrate that
FQ attaches preferentially to lysine in the peptides, and
photoadducts between FQ and MHC-binding peptides are
responsible for the induction and elicitation of murine FQ
photoallergy.
MATERIALS AND METHODS
Animals Male BALB/c mice (H-2d), 8±9 wk old, obtained from Japan
SLC Co. (Hamamatsu, Japan), were maintained in our conventional
animal facility. In in vivo experiments, each experimental group consisted
of four or more mice.
OFLX and peptides The chemical structure of OFLX is shown in
Fig 1. OFLX was kindly provided from Daiichi Pharmaceutical Co.
(Tokyo, Japan). It is well solubilized in phosphate-buffered saline (PBS;
pH 7.4) or distilled water, as the saturated concentration is more than
40 mM. OFLX has absorption peaks in UVB (288 nm) and UVA
(333 nm) wavelength ranges, and is photodegradated upon exposure to
UVA, as assessed by alteration of absorbance spectra after UVA
irradiation of its aqueous solution (Tokura et al, 1996b).
Peptides HHHHHHHHHHHH (H12) and HHHHHHKHHHHH
(H6KH5), and those listed in Table I were synthesized with an
automated solid-phase peptide synthesizer and obtained from Afford Co.
(Tokyo, Japan). The synthetic peptides in Table I are derived from
ovalbumin (OVA) or apopolipoprotein (Apo)-E and were arbitrarily
selected on the basis of the reported ability to bind to MHC class II I-Ad
or I-As (Reizis et al, 1998) and the presence or absence of lysine (K) in
their sequences. Puri®cation of high-performance liquid chromatogra-
phy-fractionated peptides was more than 95%.
Light source Black light (FL20SBLB) emitting UVA ranging from 320
to 400 nm with a peak emission at 365 nm were purchased from
Toshiba Electric (Tokyo, Japan). With a UV radiometer (Eisai, Tokyo,
Japan), the energy output of three 20 W tubes of black light at a distance
of 20 cm was 2.7 mW per cm2 at 365 nm and 0.17 mW per cm2 at
305 nm.
Amino acid analysis of bovine serum albumin (BSA) photoreacted
with OFLX OFLX-BSA photoadducts were prepared as described
previously (Tokura et al, 1996b). Brie¯y, a mixed solution of 4 mM
OFLX and 0.1 mM BSA (Armour Pharmaceutical Co, Kankakee, IL) in
0.1 mM phosphate buffer (pH 8.0) was placed in a plastic dish (Falcon
3001, Becton Dickinson, Oxnard, CA) and irradiated with three tubes of
black light at a distance of 20 cm through a pane of 3 mm thick glass to
ensure that no radiation below 320 nm reached the solution. Under
these conditions, the irradiance that reached to the solution was 2.2 mJ
per cm2 at 365 nm. After exposure to 2 J per cm2 UVA, the solution
was dialyzed against PBS to eliminate free OFLX (cut-off, 10 kDa).
The sample of OFLX-photoreacted BSA (500 ml) and untreated
control BSA were dried and hydrolyzed with 1 ml of 6 M HCl for 20 h
at 110°C. The hydrolysates were evaporated, and the residues were
dissolved in 1 ml of water. One hundred microliters of the sample was
subjected to precolumn phenylisothiocyanate derivatization.
Phenylthiocarbamyl-amino acid amide derivatives were analyzed by
reverse phase-high-performance liquid chromatography on a Waters
Pico-Tag amino acid analysis column (Waters Corp., Milford, MA).
Phenylthiocarbamyl-amino acid amides were identi®ed and quantitated
by comparing their elution positions and peak areas, respectively, with
those of standards in a Model 835-50 automated amino acid analyzer
system (Hitachi, Tokyo, Japan).
Preparation of OFLX-peptide photoadducts Solutions of 2 mM
OFLX and 1 mM peptide in PBS were placed in a plastic dish and
irradiated with UVA (2 J per cm2 at 365 nm). This stock solution was
used at a ®nal dilution of 1:40 for in vitro pulsing of Langerhans cells. For
the use of skin application, a mixture of 4 mM OFLX and 2 mM
peptide in PBS was irradiated with the same dose of UVA and used
without dilution.
Immunoadsorption of OFLX-H12 or OFLX-H6KH5
photoadducts For immunoaf®nity column, 2 mg per ml of af®nity-
puri®ed ST-Q-9 (IgM, k), a monoclonal antibody (MoAb) speci®c to
FQ photoadducts (Tokura et al, 1998), was coupled to cyanogen
bromide-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway,
NJ) according to the manufacturer's instructions. OFLX-H12 and
OFLX-H6KH5 photoadducts were individually applied to an
immunoadsorbent column composed of ST-Q-9-Sepharose. After
reacting for 1 h at 4°C, the column was extensively washed with PBS.
The bound material was eluted from the column with acetic acid
(pH 2.85) and was neutralized immediately with 1 M sodium
bicarbonate. The eluates were sequentially separated into the same
volume of ®ve fractions. The amount of OFLX bound to peptide was
measured with a Beckman Model DU-8B spectrophotometer at 460 nm
of the absorbance wavelength excited by 312 nm light. The
concentration of histidine in the eluates was measured after hydrolysis
with an amino acid analyzer (Special Reference Laboratory, Tokyo,
Japan).
Culture medium RPMI-1640 (Gibco Laboratories, Grand Island,
MY) was supplemented with 10% heat-inactivated fetal bovine serum,
5 3 10±5 M 2-mercaptoethanol, 2 mM L-glutamine, 25 mM HEPES,
1 mM nonessential amino acids, 1 mM sodium pyruvate, and 100 mg
streptomycin per ml.
Preparation of OFLX-photomodi®ed epidermal cells and
Langerhans cell-enriched epidermal cells Epidermal cell
suspensions were prepared from the earlobes of naive mice as previously
Figure 1. Chemical structure of OFLX.
Table I. I-Ad-binding synthetic peptides used in this study
Sequence (position)
Peptide P1 P4 P6 P9 Af®nity Designation Reference
OVA 317±27 S A E S L K I S Q A V I-Ad OVA11(K+) Sette et al (1990)
OVA 318±26 A E S L K I S Q A I-Ad OVA9(K+) Sette et al (1990)
OVA 323±35 I S Q A V H A A H A E I N I-Ad OVA13(K±) Sette et al (1987)
OVA 324±32 S Q A V H A A H A I-Ad OVA9(K±) Sette et al (1987)
OVA 275±83 E R K I K V Y L P I-Ad OVAS(K+) Lamont et al (1990)
Apo-E 268±83 W A N L M E K I Q A S V A T N P I-Ad Apo-E16(K+) Hunt et al (1992)
Apo-E 272±80 M E K I Q A S V A I-Ad Apo-E9(K+) Hunt et al (1992)
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described (Tokura et al, 1993) and contained 0.5±2% I-A+ cells,
representing Langerhans cells, as determined by ¯ow cytometry using a
¯uorescein isothiocyanate-conjugated anti-I-Ad MoAb (PharMingen,
Sorrent Valley, CA). For the enrichment of Langerhans cells (Tokura et
al, 1998), epidermal cell suspensions were cultured in plastic dishes for
24 h and nonadherent cells were centrifuged over a Histopaque density
gradient (speci®c gravity: 1.083; Sigma, St. Louis, MD). The cells at the
interface (Langerhans cell-enriched epidermal cells) were washed in PBS
and contained 10±15% of I-A+ cells. For photomodi®cation (Tokura et
al, 1996b, 1998), freshly isolated epidermal cells or Langerhans cell-
enriched epidermal cells were suspended in an OFLX solution (0.2 mM)
dissolved in PBS (5 3 106 cells per ml), placed in a plastic dish and
irradiated with UVA at a distance of 20 cm (equivalent to 1.2 J per cm2
at 365 nm, measured through a plastic dish). The cells were used after
washing three times in PBS. Viability of OFLX-photomodi®ed
epidermal cells was 71%, as assessed by the trypan blue dye exclusion
test.
Sensitization of mice by subcutaneous (s.c.) injection of FQ-
photomodi®ed epidermal cells or by epicutaneous (e.c.)
application of OFLX-peptide photoadducts via barrier-disrupted
skin Mice were immunized with freshly prepared OFLX-
photomodi®ed epidermal cells (107 per 0.2 ml of PBS per mouse) by s.c.
injections into the bilateral lower dorsal ¯ank (Tokura et al, 1996b,
1998). For e.c. immunization, the skin barrier was disrupted by stripping
the shaved abdomen with cellophane tape (Nichiban, Tokyo, Japan) 12
times (Nishijima et al, 1997; Seo et al, 2000). The tape stripping allows
peptides to penetrate the epidermis and epidermal immunity to be
activated, as reported previously (Nishijima et al, 1997). At 24 h after
tape stripping, OFLX-peptide or peptide was painted on abdominal skin
at a peptide dose of 50 mg per 25 ml of PBS per mouse and the vehicle
was dried up.
In vitro proliferation of immune CD4+ cells in the presence of
Langerhans cell-enriched epidermal cells loaded with OFLX-
peptide Single cell suspensions were prepared from inguinal and
axillary lymph nodes (LN) on day 6 after s.c. immunization of mice with
FQ-photomodi®ed epidermal cells or after e.c. sensitization with OFLX-
photomodi®ed peptide. To obtain puri®ed CD4+ T cells, LN cells were
incubated for 60 min at 4°C with anti-CD4 MoAb-conjugated magnetic
beads (DYNABEADS mouse CD4, Dynal, Oslo, Norway) and the
bound cells were detached from the beads with DETACHaBEAD
mouse CD4 (Dynal) according to the manufacturer's instructions.
For peptide loading, Langerhans cell-enriched epidermal cells from
naive mice were pulsed with OFLX-peptide photoadducts or peptide as
the control at 37°C for 90 min in RPMI-1640 without fetal bovine
serum at a peptide concentration of 50 mM and a cell density of 106 cells
per ml (Seo et al, 2000).
Triplicate cultures of CD4+ cells (105 cells per well) were incubated
with OFLX-peptide-pulsed or peptide-pulsed Langerhans cell-enriched
epidermal cells in a ®nal volume of 150 ml in 96-well microtiter plates
(Corning Glass Works, Corning, NY) for 72 h at 37°C in 5% CO2 in
air. Indomethacin (Sigma) was added to the culture at a ®nal concentra-
tion of 1 mg per ml. Methyl 3H-thymidine (Amersham, Arlington, IL)
was added (1 mCi per well) 14 h before harvest. The cells were collected
on glass ®ber ®lters using a cell harvester (Cambridge Technologies,
Watertown, MA) and radio-uptake was measured in a scintillation
counter.
In vivo elicitation of photoallergy to OFLX with the systemic
administration of OFLX plus UVA irradiation Six days after e.c.
application of OFLX-peptide via barrier-disrupted skin, mice were
administered intraperitoneally (i.p.) with OFLX (2 mg per 0.2 ml of
PBS, equal to 100 mg per kg of wt), and 24 h later, the earlobes of mice
were irradiated with UVA (6 J per cm2 at 365 nm) by placing mice in a
2 cm height cage (Ohshima et al, 2000). Ear thickness was measured
before and 24 h after UVA irradiation with a dial thickness gauge
(Peacock, Tokyo, Japan) and was expressed as the mean increment in
thickness above the basal line control value.
Statistical analyses Student's t test was used to determine statistical
differences between the means. p < 0.05 was considered signi®cant.
RESULTS
OFLX photoconjugation of peptides from the preferential
photoreaction of OFLX with lysine OFLX and BSA were
mixed in a solution at a molar ratio of 40:1 and irradiated with
UVA at 2 J per cm2. An amino acid composition analysis of BSA
photoreacted with OFLX revealed that the amount of lysine was
decreased by 33% after photoreaction compared with untreated
BSA (Fig 2). No substantial change was found in the other amino
acids examined, except for methionine, which was decreased by
12%. This suggested that OFLX preferentially photobinds to lysine,
leading to alteration of the structure of lysine and the resultant
reduction of its amount. As the amount of OFLX was excess against
BSA, the incomplete reduction of lysine appeared to be caused by
lack of selective noncovalent binding of OFLX to lysine before
UVA irradiation or by incomplete ef®cacy of UVA at this dose.
To con®rm further the preferential photoconjugation of OFLX
to lysine, two synthetic peptides H12 and H6KH5 [substituted one
histidine with lysine (K)] were solubilized in an OFLX solution and
exposed to UVA. Each of the irradiated solutions was applied to the
immunoadsorbent column of Sepharose bound to ST-Q-9 MoAb,
which is speci®c to FQ photoadducts (Tokura et al, 1998) and acid
eluted from the column. Each eluate fraction was monitored in the
concentration of OFLX by measuring the absorbance at 460 nm
with the excitation wavelength of 312 nm. The eluates contained
OFLX, whose concentration was peaked in fraction 3 in both
Figure 2. The amount of lysine is decreased on amino acid
composition analysis of BSA photoreacted with OFLX. A solution
of BSA and OFLX was irradiated with UVA and subjected to amino
acid analysis. Data are expressed as the percentage reduction in each
amino acid relative to untreated BSA.
Figure 3. The concentration of OFLX is higher in OFLX-H6KH5
than OFLX-H12 photoadducts. UVA-irradiated solutions of OFLX
and H12 or H6KH5 were applied to ST-Q-9-Sepharose af®nity column.
Each fraction of the acid-eluates was measured in the amount of OFLX
with a spectrophotometer, and fraction 3 was quanti®ed in the
concentration of peptide as estimated by the amount of histidine.
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preparations (Fig 3, left); however, the amount of OFLX in
fraction 3 was higher in OFLX-H6KH5 than in OFLX-H12. As
faction 3 of H6KH5 and H12 samples contained histidine at 9.2 and
10 mM, respectively (Fig 3, right), it was considered that the
amounts of peptide conjugated with OFLX were nearly the same in
these two samples. These data suggested that H6KH5 has more
photoreactive sites for OFLX than H12 by virtue of lysine. As
compared with other amino acids, the chemical structure of lysine
is characterized by the side chain of an amino residue. Given that
amino residues are photoconjugated with OFLX, H12 may carry
one photobinding site at the N terminus, whereas H6KH5 may
have two photocoupling sites, the N-terminal and the side chain of
lysine.
Requirement of lysine for preparation of OFLX-peptide
photoconjugates antigenic for immune CD4+ T cells To
assess the antigenicity of OFLX-photoconjugated peptide
containing lysine, we examined in vitro proliferation of immune
T cells in response to OFLX-peptide presented by Langerhans cells.
CD4+ immune LN cells were produced from mice that were
sensitized s.c. with OFLX-photomodi®ed epidermal cells. For
antigenic loading, Langerhans cell-enriched epidermal cells were
precultured with OFLX-photoconjugated or unconjugated MHC
class II-binding peptides listed in Table I. CD4+ T cells were
cultured with Langerhans cell-enriched epidermal cells loaded with
each peptide.
Figure 4 summarizes representative data in two independent
series of experiments with similar results. The data are expressed as
D cpm from the baseline value of CD4+ cells cultured with
unloaded Langerhans cell-enriched epidermal cells. The I-Ad-
binding, lysine-containing peptides used in this study included
OVA11(K+), OVA9(K+), Apo-E16(K+), and Apo-E9(K+). Most
notably, OVA9(K+) photoconjugated with OFLX induced a
signi®cantly higher level of proliferation of immune LN CD4+ T
cells than the unconjugated peptide. Despite the same sequence
from P1 to P9, OVA11(K+) did not stimulate immune T cells. The
proliferative responses to Apo-E16(K+) and Apo-E9(K+) photo-
coupled with OFLX were signi®cantly higher than those to the
corresponding unconjugated ones. Although they shared the
peptide sequence of P1±P9, Apo-E16(K+) gave rise to a stronger
response even when it was unconjugated with OFLX, whereas
Apo-E9(K+) yielded a weaker response even in its photomodi®ed
form. It was noteworthy that the I-Ad-binding but lysine-lacking
peptides, OVA13(K±) and OVA9(K±), and the lysine-containing
but I-As-binding peptide, OVAS(K+), produced no T cell
proliferation. Thus, peptides derived from OVA and Apo-E with
a speci®city to I-Ad created class II-restricted photohapten
determinants for T cells speci®c for OFLX photoadducts with
different antigenic intensity depending on the peptide sequence and
length.
Capability of OFLX-peptide photoadducts to in vivo
sensitize mice To test the ability of OFLX-derivatized peptide
to prime animals, mice were sensitized e.c. with an OFLX-
photocoupled I-Ad-binding, lysine-containing peptide. We chose
OVA9(K+) because of its relatively high ability to stimulate
immune T cells upon conjugation as well as its low background
stimulatory capacity when unconjugated. For immunization, the
peptide was applied to the barrier-disrupted skin (Seo et al, 2000).
The challenge was performed with an i.p. injection of OFLX and
subsequent irradiation of earlobes in order to mimic human FQ
photosensitivity (Tokura et al, 1998; Ohshima et al, 2000). As
shown in Fig 5, a signi®cant ear swelling response was evoked
upon challenge in mice painted with OFLX-OVA9(K+), but not
nonirradiated OFLX/OVA9(K+) mixture or OVA9(K+) alone, as
compared with the response of control mice without sensitization.
The intensity of response induced by OFLX-photomodi®ed
peptide was comparable with that by s.c. OFLX-photomodi®ed
epidermal cells. These results demonstrated that OFLX-peptide
photoadducts are capable of inducing OFLX photoallergy.
We next examined the in vitro response of T cells from OFLX-
peptide-primed mice. Figure 6 shows that CD4+ LN cells from
mice immunized with OFLX-OVA9(K+) (OFLX-peptide) re-
Figure 4. Proliferation of immune CD4+ T cells in response to
Langerhans cells pulsed with OFLX-photoconjugated, I-Ad-
binding peptides. CD4+ cells were puri®ed with immunomagnetic
beads from LN cells of mice immunized s.c. with OFLX-photomodi®ed
epidermal cells. Langerhans cell-enriched epidermal cells from naive mice
were precultured with the indicated peptide that were photoconjugated
or unconjugated with OFLX. CD4+ cells and Langerhans cell-enriched
epidermal cells thus prepared were cocultured for 3 d and the
proliferative response of CD4+ cells was measured by 3H-thymidine
incorporation. Data are expressed as D cpm of OFLX-peptide or peptide
responses: (cpm of culture in the presence of Langerhans cells loaded
with OFLX-peptide or peptide ± cpm of culture in the presence of
unloaded Langerhans cells). Error bars represent SD. *p < 0.05,
compared with OFLX-unconjugated group.
Figure 5. Induction of OFLX photoallergy by e.c. application of
OFLX-photoconjugated, I-Ad-binding peptides. Mice were
sensitized e.c. with OVA9(K+) that were photoconjugated with OFLX
(OFLX-peptide), incubated simply without UVA irradiation (OFLX/
peptide), or untreated (peptide). As control sensitization, mice received
s.c. injections of OFLX-photomodi®ed syngeneic epidermal cells. Six
days after immunization, they were administered i.p. with OFLX and
irradiated 24 h later with UVA on the earlobes. The ear swelling
response was measured 24 h after irradiation. Error bars represent SD. *p
< 0.05, compared with no sensitization group.
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sponded well to Langerhans cell-enriched epidermal cells pulsed
with the same photoconjugated peptide (OFLX-peptide). The T
cells proliferated moderately in response to OVA9(K+) incubated
with OFLX without UVA exposure (OFLX/peptide) as well as
OVA9(K+) (peptide) per se, compared with the no loading
Langerhans cell-enriched epidermal cells. CD4+ cells from animals
immunized with OVA9(K+) alone (peptide) proliferated less
strongly upon stimulation with OFLX-OVA9(K+) (OFLX-pep-
tide) and exhibited comparable responses with OFLX/OVA9(K+)
(OFLX/peptide) and OVA9(K+) (peptide). The results suggested
that OFLX-peptide induces immunity to both OFLX photoadduct
and peptide itself and the former is associated with OFLX
photoallergy.
DISCUSSION
This study demonstrated that OFLX photobinds preferentially, but
not exclusively, to lysine. Because of the presence of two amino
residues, lysine gives a free amino residue when situated in peptides.
Providing that OFLX is photoreacted with free amino groups to
form covalent photoadducts, both the amino residues of lysine and
N-terminus in peptides may be the binding sites. It is thus assumed
that H6KH5 and H12 carry two and one photocoupling sites,
respectively, for OFLX, which is consistent with the result obtained
from our ST-Q-9 af®nity chromatographic analysis. Lysine has also
been reported to be the major amino acid bound to haptenic drug
penicillin (Weltzien and Padovan, 1998) and ordinary hapten
trinitrophenyl (Ortmann et al, 1992).
To examine the antigenicity of OFLX-peptide photoadducts, we
®rst used the in vitro culture system consisting of: (i) CD4+ T cells
from mice immunized with OFLX-photomodi®ed epidermal cells,
which are proven to mediate FQ photoallergy (Tokura et al, 1998);
(ii) Langerhans cells, playing a crucial part as antigen-presenting
cells in the induction and elicitation of the photoallergy (Tokura et
al, 1998; Ohshima et al, 2000); and (iii) OFLX-photoconjugated, I-
Ad-anchoring peptides, containing at least one lysine residue within
the assumed T cell receptor contact area (Reizis et al, 1998). It is
not known why the responses of T cells to individual OFLX-
peptides varied, and some peptides such as Apo-E16(K+) induced a
rather strong OFLX-irrelevant T cell response. We, nevertheless,
found that the lysine-containing motif with af®nity to I-Ad, as
represented by OVA9(K+), evoked the T cell proliferative
responses when presented by Langerhans cells, whereas class II-
unmatched or lysine-lacking peptide did not. It is unlikely that
OFLX-photoderivatized proteins in the photomodi®ed murine
epidermal cells used as immunogen share peptide sequences with
the synthetic peptides derived from species other than mice,
implying that the peptide is not substantially involved in the
antigenic epitope.
Epicutaneous application of OFLX-OVA9(K+) via barrier-
disrupted skin successfully induced OFLX photoallergy as strong
as the response to s.c. OFLX-photomodi®ed epidermal cells.
This indicates the clinically relevant antigenicity of the
photomodi®ed peptide, which is ampli®ed by application via
barrier-disrupted skin (Nishijima et al, 1997; Seo et al, 2000).
CD4+ T cells from mice sensitized in this way also responded
well in vitro in response to Langerhans cells pulsed with the
same photoconjugated motif; however, weaker but signi®cant T
cell responses were observed, even when CD4+ cells of
unconjugated peptide-immunized mice were used as responders
and when unconjugated or simply OFLX-incubated peptides
were employed for pulsing Langerhans cells. This suggests that
unmodi®ed peptides have native antigenicity, and OFLX
modi®cation additionally affords photohaptenic moieties, thereby
inducing both photosensitivity to OFLX and ordinary sensitivity
to the peptide. It should be noted that skin application of
OFLX-modi®ed, class II-binding peptide does not exactly
re¯ect clinical photoallergy, as not only class II-binding self
peptides but also class I-binding self peptides are likely
photomodi®ed with OFLX in clinical settings, resulting in
induction of both CD4+ and C8+ T cell responses.
In ordinary drug-induced allergic disorders, it has been
demonstrated that CD4+ T cells are capable of interacting with
autologous cells modi®ed with a haptenic drug. Identi®cation of
the hapten-associated determinants activating allergenic T cells
has been a central issue in this response. As CD4+ T cells
interact with haptens, particularly at the reasonably low hapten
density, in an MHC-dependent way (Weltzien et al, 1996),
covalent modi®cation of MHC class II molecules with haptens,
either direct or indirect, seems to be a requirement. Two
structural possibilities can be envisaged to form a T cell-
antigenic hapten epitope: the hapten might be covalently
attached either to the MHC molecule itself, or to the associated
peptides. The general importance of haptenated peptides as
major hapten epitopes is corroborated in trinitrophenyl-speci®c
CD4+ T cells (Cavani et al, 1995; Kohler et al, 1995),
azobenzene arsonate-speci®c CD4+ T cells (Nalefski and Rao,
1993), and trinitrophenyl-speci®c CD8+ T cells (von Bonin et
al, 1992). These experimental systems have demonstrated no
requirement of direct covalent modi®cation of MHC molecules.
In trinitrophenyl and penicillin sensitivity systems, individual
MHC/peptide-speci®c T cell receptors recognize hapten on
different MHC class II-binding peptides (Weltzien et al, 1996;
Padovan et al, 1997; Weltzien and Padovan, 1998). Thus, the
sequence of the carrier peptides appears to contribute little to
the antigenic speci®city, and the peptide simply serves to
anchor and position the hapten within the MHC binding
groove (Martin and Weltzien, 1994; Kohler et al, 1995, 1997).
Accordingly, in our study, the nonself sequences of the peptides
stimulated photohapten-sensitized CD4+ T cells, and the
different I-A-binding peptides promiscuously created photohap-
ten determinants, further supporting the hapten-anchoring role
of peptides.
This study suggests that OFLX-peptide photodeterminants
formed by virtue of a photoreactive role of lysine are responsible
for the induction and elicitation of OFLX photoallergy. In clinical
photoallergy to FQ, we can assume that the drug photobinds to self
Figure 6. In vitro proliferation of CD4+ T cells from mice
sensitized e.c. with OFLX-peptide photoadducts in response to
OFLX-photoconjugated, I-Ad-binding peptides. OFLX-OVA9(K+)
was used as the peptide in this study. CD4+ cells from mice sensitized
e.c. with OFLX-peptide photoconjugates or peptide itself were cultured
with Langerhans cell-enriched epidermal cells loaded with peptide that
were photoconjugated with OFLX (OFLX-peptide), incubated without
UVA irradiation (OFLX/peptide), or untreated (peptide). 3H-thymidine
incorporation was measured after 72 h cultivation. Error bars represent
SD. *p < 0.05, compared with no loading group. **p < 0.05, compared
with OFLX/peptide and peptide groups.
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peptides on MHC class II molecules of Langerhans cells, thereby
sensitizing and restimulating T cells. The development of FQ less
photoaf®nitive to peptide/protein may avoid the photosensitive
adverse effect of these widely used drugs.
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